ST生物(000504.SZ):擬與財信產業基金共同出資設立健康產業投資基金
格隆匯 8 月 16日丨ST生物(000504.SZ)公佈,公司於2020年8月16日召開第十屆董事會第十五次臨時會議,審議通過了《關於出資參與設立健康產業投資基金暨關聯交易的提案》。
根據公司股東上海和平大宗股權投資基金管理有限公司提議,為把握商業機會,投資優質項目,公司擬與湖南省財信產業基金管理有限公司(“財信產業基金)以契約型等法定形式共同出資設立健康產業投資基金。並授權公司經營層辦理包括但不限於基金設立、籤署基金合同、託管合同等相關事宜。
此次投資事項根據《公司章程》相關規定,還需提交公司股東大會審議。
基金規模5億元人民幣,財信產業基金及相關銀行或投資機構認繳4億元,南華生物認繳1億元。基金投向:幹細胞、免疫細胞的儲存及治療、健康管理中心、血液管理中心、醫院及大健康相關項目的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.